Hungary’s largest drugmaker Gedeon Richter (RICHT: HB) says that it has entered into a license and distribution agreement with German pharma major Bayer (BAYN: DE) to sell a contraceptive of Bayer in the European Union.
Richter has agreed with Bayer HealthCare to commercialize the low dose gestodene and ethinylestradiol containing transdermal contraceptive patch of Bayer in the European Union, in other European countries and also in certain Latin American countries under the trade mark of Lisvy. National marketing authorizations have been gradually granted in the majority of European countries following the approval in the European Union in the first quarter 2014.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze